Some stock data isn't available right now.
Karyopharm Therapeutics Inc. (KPTI)
Underlying price
-- today
Stock stats
- -
- -
- -
- -
- $0.017 – $10.99
- -
- 8.63M
- -
- -
- -$14.33
- -
- 1.23
Analysts & earnings
Analyst ratings
Buy, 4.20 on a scale from 1, strong sell, to 5, strong buy
- 2 Strong buy
- 2 Buy
- 1 Hold
- 0 Sell
- 0 Strong sell
$7.33
- Target
- $7.33
Earnings per share
Beat estimates 1 of last 4
- Estimate
- Actual
- Nov '25: actual -$3.82, estimate -$3.25
- Feb '26: actual -$2.23, estimate -$2.00
- May '26: actual -$1.24, estimate -$1.44
- Aug '26: actual -$2.32, estimate -$1.53
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
- Ticker
- KPTI
- Asset class
- Equity
- Tokenized by
- 0 issuers
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Employees
- 228
- Website
- karyopharm.com